ArticleTranslational gastroenterology and hepatology2025
Trends in epidemiology, clinicopathological characteristics and survival outcomes among patients with synchronous early-onset colorectal liver metastases in the United States from 2010 to 2019.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological, prognostic, and molecular differences between microsatellite-stable colorectal cancer patients aged ≤ 30 years and > 30 years.BMC cancer · 2026Article
- Thermal ablation versus surgical resection for colorectal liver metastases: a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-assessed systematic review, survival meta-analysis, and meta-regression.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset colorectal cancer (EO-CRC), defined as being diagnosed before the age of 50 years, is becoming increasingly prevalent. Among these patients, synchronous early-onset colorectal liver metastases (EO-CRLM) have emerged as a leading cause of mortality. This study aims to investigate the epidemiology, clinicopathological characteristics, and survival outcomes related to synchronous EO-CRLM to provide a clearer understanding of the challenges faced by patients with synchronous EO-CRLM. Methods: The National Cancer Database was queried for patients with synchronous CRLM diagnosed from 2010 to 2019. Patients were then stratified by age of onset: EO-CRLM (younger than 50 years old) and late-onset colorectal liver metastases (LO-CRLM) (50 years old or older). The incidence, limited-duration prevalence rates (over a 10-year period), clinicopathological characteristics and overall survival (OS) were assessed. Results: Among 115,422 patients with CRLM, EO-CRLM and LO-CRLM were observed in 17,536 (15.2%) patients and in 97,886 (84.8%) patients, respectively. The annual age-adjusted incidence of EO-CRLM increased from 0.48 to 0.69 per 100,000 population from 2010 to 2019 [average annual percentage change (AAPC): 5.1, 95% confidence interval (CI): 4.1 to 6.1], significantly faster than that of LO-CRLM (AAPC difference: 3.5, 95% CI: 2.5 to 4.5; P<0.001). The 10-year limited-duration prevalence for EO-CRLM increased from 0.0004% in 2010 to 0.0020% in 2019 (AAPC: 15.7, 95% CI: 10.2 to 21.5). A comparison of the clinicopathological features revealed that, compared with LO-CRLM, EO-CRLM patients were more likely to reside in urban areas, have higher rates of high school completion, have higher income, and be covered by private insurance/managed care. Genetic analysis revealed EO-CRLM with microsatellite instability (MSI)-high had the largest increase of AAPC of 28.7 (95% CI: 13.1 to 46.3) compared to MSI-low and microsatellite stability (MSS) (P<0.001). Similarly, EO-CRLM patients had a rapid rise in Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations with AAPC of 10.6 (95% CI: 8.8 to 12.5). Compared with LO-CRLM, EO-CRLM was associated with improved OS in inverse probability of treatment weighting-adjusted Cox proportional hazards regression analysis (hazard ratio: 0.876, 95% CI: 0.838 to 0.915; P<0.001). Conclusions: The incidence of EO-CRLM has increased rapidly, and represents a distinct population in terms of socioeconomic and clinicopathological characteristics. Among this cohort, the prognosis of patients with EO-CRLM was favorable compared to that of patients with LO-CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.